It has been a volatile year for the biotech.

Profit taking is hitting one of biotech’s hottest trades, and the selling is landing heaviest on the stock that ran the ...

Allergic reactions after COVID shots appear only in participants with severe allergy and/or mast cell disorder histories, but ...

Pfizer PFE will announce its third-quarter 2026 earnings on Nov. 3, and investors will be watching the performance of its oncology business closely, as the segment generates nearly 27% of the ...

It comes after an immunisation program shake-up, with providers now able to set the price at their discretion.

Wall Street is quite bullish on BioNTech. In fact, among the 20 analysts covering it, 13 rate the stock a strong buy, while ...

Healthcare is drawing fresh buying as money moves away from the market’s popular technology trade, and one messenger RNA (mRNA) name is pulling well ahead of the pack. Moderna (NASDAQ:MRNA | MRNA ...

HHS says vaccine-safety studies were withdrawn because their conclusions were not supported by the data, but the unpublished ...

BioNTech has opened its clinical-scale mRNA manufacturing and research facility at La Trobe University's Bundoora campus, ...

MRNA expands beyond COVID-19 with new RSV, flu and combination vaccines, but fierce competition could challenge its efforts ...

Pfizer showcases clinical advancements across infectious diseases at IDWeek 2026: New York Thursday, October 15, 2026, 12:00 Hrs [IST] Pfizer Inc. will present data from more than ...

Shah Capital has ended its attempts to exert influence over vaccine developer Novavax, bringing more than years of activism ...